Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 203 articles:
HTML format
Text format



Single Articles


    April 2017
  1. TIRIBELLI M, Raspadori D, Geromin A, Cavallin M, et al
    High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Leuk Res. 2017;58:31-38.
    PubMed     Text format     Abstract available


    March 2017
  2. LI Y, Liu X, Guo X, Liu X, et al
    DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
    Leuk Res. 2017;58:9-13.
    PubMed     Text format     Abstract available


  3. BILOUS N, Abramenko I, Saenko V, Chumak A, et al
    Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
    Leuk Res. 2017;58:1-8.
    PubMed     Text format     Abstract available


  4. GARCIA C, Rosen A, Kimby E, Aguilar-Santelises M, et al
    Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].
    Leuk Res. 2017 Mar 14. pii: S0145-2126(17)30041.
    PubMed     Text format    


  5. GRANADOS-RIVERON JT, Aquino-Jarquin G
    Reversal of multidrug resistance of leukemia cells is not necessarily induced by direct miR-138/MDR1 promoter interaction.
    Leuk Res. 2017;57:55-56.
    PubMed     Text format    


    February 2017
  6. MAURO FR, Morabito F, Vincelli ID, Petrucci L, et al
    Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.
    Leuk Res. 2017;57:65-71.
    PubMed     Text format     Abstract available


  7. YAN T, Leng Y, Yang X, Gong Y, et al
    High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
    Leuk Res. 2017;57:9-19.
    PubMed     Text format     Abstract available


  8. HU Y, Dong X, Chu G, Lai G, et al
    miR-137 downregulates c-kit expression in acute myeloid leukemia.
    Leuk Res. 2017;57:72-77.
    PubMed     Text format     Abstract available


  9. KANG KW, Kim DS, Lee SR, Sung HJ, et al
    Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
    Leuk Res. 2017;57:1-8.
    PubMed     Text format     Abstract available


  10. PULTE D, Castro FA, Brenner H, Jansen L, et al
    Outcome disparities by insurance type for patients with acute myeloblastic leukemia.
    Leuk Res. 2017;56:75-81.
    PubMed     Text format     Abstract available


    January 2017
  11. QUAGLIANO A, Gopalakrishnapillai A, Barwe SP
    Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
    Leuk Res. 2017;56:36-43.
    PubMed     Text format     Abstract available


  12. YAO J, Zhang G, Liang C, Li G, et al
    Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Leuk Res. 2017;55:97-104.
    PubMed     Text format     Abstract available


  13. PATEL JL, Schumacher JA, Frizzell K, Sorrells S, et al
    Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Leuk Res. 2017;56:7-12.
    PubMed     Text format     Abstract available


  14. MOHAMED AM, Balsat M, Koering C, Maucort-Boulch D, et al
    TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
    Leuk Res. 2017;56:21-28.
    PubMed     Text format     Abstract available


  15. HUANG SJ, Lee LJ, Gerrie AS, Gillan TL, et al
    Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.
    Leuk Res. 2017;55:79-90.
    PubMed     Text format     Abstract available


  16. PORTICH JP, Dos Santos RP, Kersting N, Jorge KB, et al
    DNA damage response in patients with pediatric Acute Lymphoid Leukemia during induction therapy.
    Leuk Res. 2017;54:59-65.
    PubMed     Text format     Abstract available


  17. HATTORI A, McSkimming D, Kannan N, Ito T, et al
    RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.
    Leuk Res. 2017;54:47-54.
    PubMed     Text format     Abstract available


  18. JEVTOVIC-STOIMENOV T, Cvetkovic T, Despotovic M, Basic J, et al
    The influence of TNF alpha -308 G/A polymorphism on oxidative stress in patients with chronic lymphocytic leukemia.
    Leuk Res. 2017;54:66-72.
    PubMed     Text format     Abstract available


  19. WANG L, Raffoux E, Thomas X, Yakoub-Agha I, et al
    Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.
    Leuk Res. 2017;54:12-16.
    PubMed     Text format     Abstract available


  20. IRIYAMA N, Tokuhira M, Takaku T, Sato E, et al
    Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
    Leuk Res. 2017;54:55-58.
    PubMed     Text format     Abstract available


  21. CAO S, Lu X, Wang L, Qian X, et al
    The functional polymorphisms of LIS1 are associated with acute myeloid leukemia risk in a Han Chinese population.
    Leuk Res. 2017;54:7-11.
    PubMed     Text format     Abstract available


    December 2016
  22. MARTINELLI S, Maffei R, Fiorcari S, Quadrelli C, et al
    The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli.
    Leuk Res. 2016;54:17-24.
    PubMed     Text format     Abstract available


  23. GRONROOS T, Teppo S, Mehtonen J, Laukkanen S, et al
    Overexpression of PTP4A3 in ETV6-RUNX1 acute lymphoblastic leukemia.
    Leuk Res. 2016;54:1-6.
    PubMed     Text format     Abstract available


  24. LIU C, Zhao L, Zhao J, Xu Q, et al
    Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
    Leuk Res. 2016;53:57-64.
    PubMed     Text format     Abstract available


  25. HUANG L, Wang SA, DiNardo C, Li S, et al
    Tetraploidy/near-tetraploidy acute myeloid leukemia.
    Leuk Res. 2016;53:20-27.
    PubMed     Text format     Abstract available


    November 2016
  26. KONTOS CK, Papageorgiou SG, Diamantopoulos MA, Scorilas A, et al
    mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia.
    Leuk Res. 2016;53:65-73.
    PubMed     Text format     Abstract available


  27. UCHIDA T, Hagihara M, Hua J, Inoue M, et al
    The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
    Leuk Res. 2016;53:35-38.
    PubMed     Text format     Abstract available


  28. YIN J, Zhang F, Tao H, Ma X, et al
    Corrigendum to "BCL11A expression in acute phase chronic myeloid leukemia" [Leuk. Res. 47 (2016) 88-92].
    Leuk Res. 2016 Nov 21. pii: S0145-2126(16)30165.
    PubMed     Text format    


  29. SALSON M, Giraud M, Caillault A, Grardel N, et al
    High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
    Leuk Res. 2016;53:1-7.
    PubMed     Text format     Abstract available


  30. ZHANG YH, Lu AD, Yang L, Li LD, et al
    PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.
    Leuk Res. 2016;52:43-49.
    PubMed     Text format     Abstract available


  31. MOLONEY JN, Stanicka J, Cotter TG
    Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22phox-derived reactive oxygen species in acute myeloid leukemia.
    Leuk Res. 2016;52:34-42.
    PubMed     Text format     Abstract available


  32. VOJCEK A, Pajor G, Alpar D, Matics R, et al
    Conserved hierarchical gain of chromosome 4 is an independent prognostic factor in high hyperdiploid pediatric acute lymphoblastic leukemia.
    Leuk Res. 2016;52:28-33.
    PubMed     Text format     Abstract available


  33. CHAVEZ-GONZALEZ A, Centeno-Llanos S, Moreno-Lorenzana D, Sandoval-Esquivel MA, et al
    Casiopeina III-Ea, a copper-containing small molecule, inhibits the in vitro growth of primitive hematopoietic cells from chronic myeloid leukemia.
    Leuk Res. 2016;52:8-19.
    PubMed     Text format     Abstract available


    October 2016
  34. SABNIS HS, Bradley HL, Tripathi S, Yu WM, et al
    Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine.
    Leuk Res. 2016;50:132-140.
    PubMed     Text format     Abstract available


  35. CHEN J, Cheng J, Yi J, Xie B, et al
    Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide.
    Leuk Res. 2016;50:116-122.
    PubMed     Text format     Abstract available


    September 2016
  36. SHIMIZU R, Muto T, Aoyama K, Choi K, et al
    Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.
    Leuk Res. 2016;50:85-94.
    PubMed     Text format     Abstract available


  37. KOST SE, Bouchard ED, LaBossiere E, Ye X, et al
    Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
    Leuk Res. 2016;50:63-71.
    PubMed     Text format     Abstract available


  38. LEE NH, Choi YB, Yi ES, Lee SH, et al
    Monosomal karyotype is not a predictor of dismal outcome in childhood de novo acute myeloid leukemia.
    Leuk Res. 2016;50:57-62.
    PubMed     Text format     Abstract available


  39. HONG M, Xia Y, Zhu Y, Zhao HH, et al
    TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
    Leuk Res. 2016;50:72-77.
    PubMed     Text format     Abstract available


  40. MOLICA S, Polliack A
    Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
    Leuk Res. 2016;50:31-36.
    PubMed     Text format     Abstract available


  41. KYRTSONIS MC, Maltezas D
    New evidence of gene inactivation by aberrant DNA-Methylation in T-cell leukemia, with treatment implications.
    Leuk Res. 2016;50:29-30.
    PubMed     Text format    


  42. LOU Y, Suo S, Tong H, Qian W, et al
    Hypofibrinogenemia as a clue in the presumptive diagnosis of acute promyelocytic leukemia.
    Leuk Res. 2016;50:11-16.
    PubMed     Text format     Abstract available


  43. LECLERC GM, Zheng S, Leclerc GJ, DeSalvo J, et al
    The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2alpha and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
    Leuk Res. 2016;50:1-10.
    PubMed     Text format     Abstract available


  44. MIYAMURA K, Miyamoto T, Tanimoto M, Yamamoto K, et al
    Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
    Leuk Res. 2016;51:11-18.
    PubMed     Text format     Abstract available


  45. SUN Y, Shen H, Xu T, Yang Z, et al
    Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Leuk Res. 2016;49:102-107.
    PubMed     Text format     Abstract available


  46. VISANI G, Manti A, Valentini L, Canonico B, et al
    Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia.
    Leuk Res. 2016;50:50-56.
    PubMed     Text format     Abstract available


    August 2016
  47. HORVAT TZ, Pecoraro JJ, Daley RJ, Buie LW, et al
    The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Leuk Res. 2016;50:17-20.
    PubMed     Text format     Abstract available


  48. JASTANIAH W, Al Ghemlas I, Al Daama S, Ballourah W, et al
    Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Leuk Res. 2016;49:66-72.
    PubMed     Text format     Abstract available


  49. BERMAN E, Jhanwar S, Hedvat C, Arcila ME, et al
    Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL135INS.
    Leuk Res. 2016;49:108-112.
    PubMed     Text format     Abstract available


    July 2016
  50. FARHADFAR N, Litzow MR
    New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Leuk Res. 2016;49:13-21.
    PubMed     Text format     Abstract available


  51. RAVANDI F, Gojo I, Patnaik MM, Minden MD, et al
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
    Leuk Res. 2016;48:92-100.
    PubMed     Text format     Abstract available


  52. WATTS JM, Dumitriu B, Hilden P, Kishtagari A, et al
    Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia.
    Leuk Res. 2016;49:62-65.
    PubMed     Text format     Abstract available


  53. GHOBADI A, Choi J, Fiala MA, Fletcher T, et al
    Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
    Leuk Res. 2016;49:1-6.
    PubMed     Text format     Abstract available


  54. PRASAD V, Gale RP
    Precision medicine in acute myeloid leukemia: Hope, hype or both?
    Leuk Res. 2016;48:73-77.
    PubMed     Text format     Abstract available


  55. SHIN TH, Brynczka C, Dayyani F, Rivera MN, et al
    TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.
    Leuk Res. 2016;48:46-56.
    PubMed     Text format     Abstract available


  56. COCULOVA M, Imrichova D, Seres M, Messingerova L, et al
    The expression of P-glycoprotein in leukemia cells is associated with the upregulated expression of nestin, a class 6 filament protein.
    Leuk Res. 2016;48:32-39.
    PubMed     Text format     Abstract available


  57. HARTSOCK B, Lim MJ, Roth CG, Raptis N, et al
    ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia.
    Leuk Res. 2016;48:16-19.
    PubMed     Text format     Abstract available


  58. BRECCIA M, Molica M, Colafigli G, Massaro F, et al
    Early molecular response in chronic myeloid leukemia and halving time: Latest evidences.
    Leuk Res. 2016;48:20-25.
    PubMed     Text format     Abstract available


    June 2016
  59. MATUSZAK M, Lewandowski K, Czyz A, Kiernicka-Parulska J, et al
    The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia.
    Leuk Res. 2016;47:166-171.
    PubMed     Text format     Abstract available


  60. TIMILSHINA N, Breunis H, Tomlinson G, Brandwein J, et al
    Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?
    Leuk Res. 2016;47:142-148.
    PubMed     Text format     Abstract available


  61. GRIGNANO E, Mekinian A, Braun T, Liozon E, et al
    Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.
    Leuk Res. 2016;47:136-141.
    PubMed     Text format     Abstract available


    May 2016
  62. MUSTO P, Negrini M, De Luca L, Cuneo A, et al
    Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile: Editorial for the paper "MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion".
    Leuk Res. 2016;47:114-115.
    PubMed     Text format    


  63. SHIRAI Y, Miyashita M, Kawa M, Motokura T, et al
    Evaluation of care for leukemia and lymphoma patients during their last hospitalization from the perspective of the bereaved family.
    Leuk Res. 2016;47:93-99.
    PubMed     Text format     Abstract available


  64. CHATTERJEE R, Chattopadhyay S, Law S
    Alteration of classical and hematopoiesis specific p53 pathway in the bone marrow hematopoietic stem/progenitor compartment facilitates leukemia progression in experimental mice.
    Leuk Res. 2016;47:70-77.
    PubMed     Text format     Abstract available


  65. YIN J, Zhang F, Tao H, Ma X, et al
    BCL11A expression in acute phase chronic myeloid leukemia.
    Leuk Res. 2016;47:88-92.
    PubMed     Text format     Abstract available


  66. WANG J, Hu J, Jin Z, Wan H, et al
    The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Leuk Res. 2016;47:32-40.
    PubMed     Text format     Abstract available


  67. STOSKUS M, Eidukaite A, Griskevicius L
    Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells.
    Leuk Res. 2016;47:16-21.
    PubMed     Text format     Abstract available


  68. CHAVEZ JC, Piris-Villaespesa M, Dalia S, Powers J, et al
    Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Leuk Res. 2016;47:78-83.
    PubMed     Text format     Abstract available


  69. ISHIYAMA K, Yamaguchi T, Eto T, Ohashi K, et al
    Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT.
    Leuk Res. 2016;47:47-53.
    PubMed     Text format     Abstract available


  70. TANG FF, Huang XJ, Zhang XH, Chen H, et al
    Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
    Leuk Res. 2016;47:8-15.
    PubMed     Text format     Abstract available


  71. MANZONI D, Catallo R, Chebel A, Baseggio L, et al
    The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
    Leuk Res. 2016;47:1-7.
    PubMed     Text format     Abstract available


  72. MAGWOOD-GOLSTON JS, Kessler S, Bennett CL
    Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry.
    Leuk Res. 2016;44:61-4.
    PubMed     Text format     Abstract available


  73. GENG S, Yao H, Weng J, Tong J, et al
    Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
    Leuk Res. 2016;44:17-24.
    PubMed     Text format     Abstract available


    April 2016
  74. SEITER K, Ahmed N, Shaikh A, Baskind P, et al
    CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
    Leuk Res. 2016;46:74-78.
    PubMed     Text format     Abstract available


  75. FANG J, Zhang R, Wang H, Hong M, et al
    Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
    Leuk Res. 2016;46:61-68.
    PubMed     Text format     Abstract available


  76. MIAN YA, Zeleznik-Le NJ
    The miR-17 approximately 92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
    Leuk Res. 2016;46:51-60.
    PubMed     Text format     Abstract available


  77. VAN DE VELDE AL, Beutels P, Smits EL, Van Tendeloo VF, et al
    Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.
    Leuk Res. 2016;46:26-29.
    PubMed     Text format     Abstract available


  78. HERNANDEZ-SANCHEZ M, Rodriguez-Vicente AE, Hernandez JA, Lumbreras E, et al
    MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
    Leuk Res. 2016;46:30-36.
    PubMed     Text format     Abstract available


  79. WANG Q, Li Y, Cheng J, Chen L, et al
    Sam68 affects cell proliferation and apoptosis of human adult T-acute lymphoblastic leukemia cells via AKT/mTOR signal pathway.
    Leuk Res. 2016;46:1-9.
    PubMed     Text format     Abstract available


  80. SAINI L, Brandwein J, Turner R, Larratt L, et al
    Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.
    Leuk Res. 2016;45:47-52.
    PubMed     Text format     Abstract available


  81. TANAHASHI T, Sekiguchi N, Matsuda K, Takezawa Y, et al
    Cell size variations of large granular lymphocyte leukemia: Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations.
    Leuk Res. 2016;45:8-13.
    PubMed     Text format     Abstract available


  82. TIAN H, Xu Y, Liu L, Yan L, et al
    Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone.
    Leuk Res. 2016;45:40-46.
    PubMed     Text format     Abstract available


  83. MIRJI G, Bhat J, Kode J, Banavali S, et al
    Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.
    Leuk Res. 2016;45:33-39.
    PubMed     Text format     Abstract available


  84. NISHIOKA C, Ikezoe T, Yang J, Yokoyama A, et al
    BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells.
    Leuk Res. 2016;45:24-32.
    PubMed     Text format     Abstract available


  85. VAUGHN JE, Buckley SA, Walter RB
    Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations.
    Leuk Res. 2016;45:53-58.
    PubMed     Text format     Abstract available


  86. LI XM, Zhang LP, Wang YZ, Lu AD, et al
    CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients.
    Leuk Res. 2016;43:33-8.
    PubMed     Text format     Abstract available


    March 2016
  87. WENG XQ, Sheng Y, Ge DZ, Wu J, et al
    RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBPbeta, C/EBPepsilon and PU.1.
    Leuk Res. 2016;45:68-74.
    PubMed     Text format     Abstract available


  88. HO H, Skaist AM, Pallavajjala A, Yonescu R, et al
    NUP98-PHF23 fusion is recurrent in acute myeloid leukemia and shares gene expression signature of leukemic stem cells.
    Leuk Res. 2016;45:1-7.
    PubMed     Text format     Abstract available


  89. MOLTENI A, Riva M, Borin L, Bernardi M, et al
    The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
    Leuk Res. 2016;42:21-7.
    PubMed     Text format     Abstract available


  90. CARRETT-DIAS M, Almeida LK, Pereira JL, Almeida DV, et al
    Cell differentiation and the multiple drug resistance phenotype in human erythroleukemic cells.
    Leuk Res. 2016;42:13-20.
    PubMed     Text format     Abstract available


  91. XIAO D, Shi Y, Fu C, Jia J, et al
    Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.
    Leuk Res. 2016;42:75-9.
    PubMed     Text format     Abstract available


    February 2016
  92. ZHU HH, Jiang H, Jiang Q, Jia JS, et al
    Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
    Leuk Res. 2016;44:40-44.
    PubMed     Text format     Abstract available


  93. RADIVOYEVITCH T, Sachs RK, Gale RP, Smith MR, et al
    Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia.
    Leuk Res. 2016;43:9-12.
    PubMed     Text format     Abstract available


  94. FRAISON JB, Mekinian A, Grignano E, Kahn JE, et al
    Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Res. 2016;43:13-17.
    PubMed     Text format     Abstract available


  95. PEARSON E, McGarry L, Gala S, Nieset C, et al
    Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy.
    Leuk Res. 2016;43:1-8.
    PubMed     Text format     Abstract available


  96. GRIFFITHS EA, Brady WE, Tan W, Vigil CE, et al
    A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2016;43:44-48.
    PubMed     Text format     Abstract available


  97. SULEIMAN Y, Dalia S, Liu JJ, Bowers JW, et al
    Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Res. 2016;42:52-58.
    PubMed     Text format     Abstract available


  98. BAINSCHAB A, Quehenberger F, Greinix HT, Krause R, et al
    Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
    Leuk Res. 2016;42:47-51.
    PubMed     Text format     Abstract available


  99. PULLARKAT V
    Treatment of the older adult with ALL: An urgent call to action.
    Leuk Res. 2016;41:3-4.
    PubMed     Text format    


  100. WAMPFLER J, Federzoni EA, Torbett BE, Fey MF, et al
    The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation.
    Leuk Res. 2016;41:96-102.
    PubMed     Text format     Abstract available


  101. GUPTA SK, Bakhshi S, Kumar L, Seth R, et al
    IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
    Leuk Res. 2016;41:7-11.
    PubMed     Text format     Abstract available


    January 2016
  102. CHEN H, Wang N, Yang G, Guo Y, et al
    The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.
    Leuk Res. 2016;42:28-36.
    PubMed     Text format     Abstract available


  103. MINETTO P, Guolo F, Miglino M
    Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia.
    Leuk Res. 2016 Jan 22. pii: S0145-2126(16)30005.
    PubMed     Text format    


  104. NAREN D, Wu J, Gong Y, Yan T, et al
    Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
    Leuk Res. 2016 Jan 16. pii: S0145-2126(16)30007.
    PubMed     Text format     Abstract available


  105. ACHILLE NJ, Othus M, Phelan K, Zhang S, et al
    Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.
    Leuk Res. 2016 Jan 15. pii: S0145-2126(16)30004.
    PubMed     Text format     Abstract available


  106. SAROVA I, Brezinova J, Zemanova Z, Ransdorfova S, et al
    Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.
    Leuk Res. 2016 Jan 8. pii: S0145-2126(16)30001.
    PubMed     Text format     Abstract available


  107. NISCOLA P, Cupelli L, Dentamaro T, Fabritiis P, et al
    Chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia: a way to improve the outcome?
    Leuk Res. 2016 Jan 4. pii: S0145-2126(15)30571.
    PubMed     Text format    


  108. MINAKATA D, Fujiwara SI, Ito S, Mashima K, et al
    A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Leuk Res. 2016 Jan 2. pii: S0145-2126(15)30570.
    PubMed     Text format     Abstract available


  109. LOU YJ, Pan XR, Jia PM, Jin J, et al
    RIG-G inhibits the proliferation of NB4 cells and propels ATRA-induced differentiation of APL cells.
    Leuk Res. 2016;40:83-9.
    PubMed     Text format     Abstract available


  110. VETTER T, Borowski A, Wohlmann A, Ranjan N, et al
    Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.
    Leuk Res. 2016;40:38-43.
    PubMed     Text format     Abstract available


  111. MELE G, Coppi MR, Guaragna G, Spina A, et al
    Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.
    Leuk Res. 2016;40:30-2.
    PubMed     Text format     Abstract available


  112. KELLNER J, Wierda W, Shpall E, Keating M, et al
    Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL.
    Leuk Res. 2016;40:54-9.
    PubMed     Text format     Abstract available


  113. VIDRIALES MB, Perez-Lopez E, Pegenaute C, Castellanos M, et al
    Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
    Leuk Res. 2016;40:1-9.
    PubMed     Text format     Abstract available


  114. MONTANO G, Ullmark T, Jernmark-Nilsson H, Sodaro G, et al
    The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.
    Leuk Res. 2016;40:60-7.
    PubMed     Text format     Abstract available


    December 2015
  115. ITONAGA H, Iwanaga M, Aoki K, Aoki J, et al
    Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
    Leuk Res. 2015 Dec 24. pii: S0145-2126(15)30561.
    PubMed     Text format     Abstract available


  116. CHIARETTI S, Brugnoletti F, Messina M, Paoloni F, et al
    CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
    Leuk Res. 2015 Dec 23. pii: S0145-2126(15)30557.
    PubMed     Text format     Abstract available


  117. ZHOU L, Liu X, Wang X, Sun Z, et al
    CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Leuk Res. 2015 Dec 19. pii: S0145-2126(15)30560.
    PubMed     Text format     Abstract available


  118. SEITER K
    Therapy for relapsed acute lymphoblastic leukemia: Still a role for standard chemotherapy regimens?
    Leuk Res. 2015 Dec 19. pii: S0145-2126(15)30564.
    PubMed     Text format    


  119. GHASEMZADEH M, Hosseini E, Schwarer AP, Pourfathollah AA, et al
    NK cell maturation to CD56 subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2015 Dec 17. pii: S0145-2126(15)30559.
    PubMed     Text format     Abstract available


  120. ANDERSSON BS
    Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion?: Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An ana
    Leuk Res. 2015 Dec 12. pii: S0145-2126(15)30554.
    PubMed     Text format    


  121. TAO H, Ma X, Su G, Yin J, et al
    BCL11A expression in acute myeloid leukemia.
    Leuk Res. 2015 Dec 7. pii: S0145-2126(15)30558.
    PubMed     Text format     Abstract available


  122. BERMAN E, Maloy M, Devlin S, Jhanwar S, et al
    Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.
    Leuk Res. 2015 Dec 2. pii: S0145-2126(15)30549.
    PubMed     Text format     Abstract available


  123. RIBERA JM, Garcia O, Oriol A, Gil C, et al
    Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.
    Leuk Res. 2015 Dec 2. pii: S0145-2126(15)30552.
    PubMed     Text format     Abstract available


  124. FAN SJ, Li HB, Cui G, Kong XL, et al
    miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia.
    Leuk Res. 2015 Dec 1. pii: S0145-2126(15)30556.
    PubMed     Text format     Abstract available


  125. ABDELHAMED S, Kurre P
    Hope and hype surrounding circulating microRNA as potential next generation AML biomarkers.
    Leuk Res. 2015;39:1309-11.
    PubMed     Text format    


  126. BADAR T, Patel KP, Thompson PA, DiNardo C, et al
    Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Leuk Res. 2015;39:1367-74.
    PubMed     Text format     Abstract available


  127. DAMDINSUREN A, Matsushita H, Ito M, Tanaka M, et al
    FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
    Leuk Res. 2015;39:1405-13.
    PubMed     Text format     Abstract available


  128. KOUTOVA L, Sterbova M, Pazourkova E, Pospisilova S, et al
    The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
    Leuk Res. 2015;39:1389-95.
    PubMed     Text format     Abstract available


    November 2015
  129. LANDFELDT E, Eriksson J, Ireland S, Musingarimi P, et al
    Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
    Leuk Res. 2015 Nov 12. pii: S0145-2126(15)30546.
    PubMed     Text format     Abstract available


    October 2015
  130. SASAKI R, Ito S, Asahi M, Ishida Y, et al
    YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.
    Leuk Res. 2015 Oct 27. pii: S0145-2126(15)30537.
    PubMed     Text format     Abstract available


  131. JANCZAR K, Janczar S, Pastorczak A, Mycko K, et al
    Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.
    Leuk Res. 2015 Oct 20. pii: S0145-2126(15)30531.
    PubMed     Text format     Abstract available


  132. ZEIDNER JF, Karp JE
    Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
    Leuk Res. 2015 Oct 19. pii: S0145-2126(15)30536.
    PubMed     Text format     Abstract available


  133. LIU N, Ning HM, Hu LD, Jiang M, et al
    Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
    Leuk Res. 2015 Oct 19. pii: S0145-2126(15)30533.
    PubMed     Text format     Abstract available


  134. SMOL T, Nibourel O, Marceau-Renaut A, Celli-Lebras K, et al
    Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.
    Leuk Res. 2015 Oct 9. pii: S0145-2126(15)30392.
    PubMed     Text format     Abstract available


  135. UY GL, Hsu YS, Schmidt AP, Stock W, et al
    Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
    Leuk Res. 2015 Oct 1. pii: S0145-2126(15)30391.
    PubMed     Text format     Abstract available


  136. GANSTER C, Shirneshan K, Salinas-Riester G, Braulke F, et al
    Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
    Leuk Res. 2015;39:1079-87.
    PubMed     Text format     Abstract available


  137. WANG WZ, Pu QH, Lin XH, Liu MY, et al
    Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
    Leuk Res. 2015;39:1117-24.
    PubMed     Text format     Abstract available


  138. PARK SH, Park CJ, Kim DY, Lee BR, et al
    MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation.
    Leuk Res. 2015;39:1109-16.
    PubMed     Text format     Abstract available


  139. MAKSIMOVIC-IVANIC D, Mojic M, Bulatovic M, Radojkovic M, et al
    The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
    Leuk Res. 2015;39:1088-95.
    PubMed     Text format     Abstract available


    September 2015
  140. ARONS E, Zhou H, Edelman DC, Gomez A, et al
    Impact of telomere length on survival in classic and variant hairy cell leukemia.
    Leuk Res. 2015 Sep 24. pii: S0145-2126(15)30386.
    PubMed     Text format     Abstract available


  141. TIAN X, Wang Y, Zhao F, Liu J, et al
    A new classification of interphase nuclei based on spatial organizations of chromosome 8 and 21 for t(8;21) (q22;q22) acute myeloid leukemia by three-dimensional fluorescence in situ hybridization.
    Leuk Res. 2015 Sep 18. pii: S0145-2126(15)30384.
    PubMed     Text format     Abstract available


  142. QU Q, Liu L, Zhang Y, Li X, et al
    Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leuke
    Leuk Res. 2015 Sep 18. pii: S0145-2126(15)30385.
    PubMed     Text format     Abstract available


  143. WANG F, Liu Z, Zeng J, Zhu H, et al
    Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
    Leuk Res. 2015 Sep 18. pii: S0145-2126(15)30387.
    PubMed     Text format     Abstract available


  144. DIAMANTIDIS MD, Sogka EA
    The presence of low-count chronic lymphocytic leukemia-like monoclonal B lymphocytosis in patients with Ph-myeloproliferative neoplasms: A random event or a shared causal pathobiology?
    Leuk Res. 2015 Sep 15. pii: S0145-2126(15)30388.
    PubMed     Text format    


  145. GIRI S, Chi M, Johnson B, McCormick D, et al
    Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis.
    Leuk Res. 2015 Sep 12. pii: S0145-2126(15)30382.
    PubMed     Text format     Abstract available


  146. ADAMAKI M, Tsotra M, Vlahopoulos S, Zampogiannis A, et al
    STAT transcript levels in childhood acute lymphoblastic leukemia: STAT1 and STAT3 transcript correlations.
    Leuk Res. 2015 Sep 11. pii: S0145-2126(15)30379.
    PubMed     Text format     Abstract available


  147. PARK BG, Park CJ, Jang S, Chi HS, et al
    Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
    Leuk Res. 2015 Sep 10. pii: S0145-2126(15)30381.
    PubMed     Text format     Abstract available


  148. DE LA PUENTE P, Weisberg E, Muz B, Nonami A, et al
    Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.
    Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377.
    PubMed     Text format     Abstract available


  149. JIANG H, Liang GW, Huang XJ, Jiang Q, et al
    Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
    Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30376.
    PubMed     Text format     Abstract available


  150. HEFAZI M, Siddiqui M, Patnaik M, Wolanskyj A, et al
    Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities.
    Leuk Res. 2015 Sep 3. pii: S0145-2126(15)30372.
    PubMed     Text format     Abstract available


    August 2015
  151. WU Q, Zhang R, Wang H, You Y, et al
    Comparison of outcomes of idarubicin intensified TBI-CY and traditional TBI-CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience.
    Leuk Res. 2015 Aug 28. pii: S0145-2126(15)30369.
    PubMed     Text format     Abstract available


  152. ALIBHAI SM, Durbano S, Breunis H, Brandwein JM, et al
    A phase II exercise randomized controlled trial for patients with acute myeloid leukemia undergoing induction chemotherapy.
    Leuk Res. 2015 Aug 28. pii: S0145-2126(15)30365.
    PubMed     Text format     Abstract available


  153. GUILLEM V, Amat P, Collado M, Cervantes F, et al
    BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.
    Leuk Res. 2015 Aug 28. pii: S0145-2126(15)30367.
    PubMed     Text format     Abstract available


  154. LI X, Liu L, Zhang Y, Qu Q, et al
    Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Res. 2015 Aug 28. pii: S0145-2126(15)30366.
    PubMed     Text format     Abstract available


  155. SINGHA AK, Bhattacharjee B, Maiti D
    Cytotoxic activity of T lymphocytes is induced upon stimulation with IL-3 plus GM-CSF in animal leukemia model.
    Leuk Res. 2015 Aug 24. pii: S0145-2126(15)30364.
    PubMed     Text format     Abstract available


  156. ZHANG XH, Wang CC, Jiang Q, Yang SM, et al
    ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia.
    Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30359.
    PubMed     Text format     Abstract available


  157. HECHT A, Nowak D, Nowak V, Hanfstein B, et al
    A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia.
    Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30363.
    PubMed     Text format     Abstract available


  158. CARVALHO DC, Wanderley AV, Amador MA, Fernandes MR, et al
    Amerindian genetic ancestry and INDEL polymorphisms associated with susceptibility of childhood B-cell Leukemia in an admixed population from the Brazilian Amazon.
    Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30361.
    PubMed     Text format     Abstract available


  159. DELIA M, Carluccio P, Buquicchio C, Vergine C, et al
    Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP).
    Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30358.
    PubMed     Text format     Abstract available


  160. MILTIADES P, Lamprianidou E, Kerzeli IK, Nakou E, et al
    Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms.
    Leuk Res. 2015 Aug 14. pii: S0145-2126(15)30357.
    PubMed     Text format     Abstract available


  161. SABA NS, Angelova M, Lobelle-Rich PA, Levy LS, et al
    Disruption of pre-B-cell receptor signaling jams the WNT/beta-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines.
    Leuk Res. 2015 Aug 10. pii: S0145-2126(15)30355.
    PubMed     Text format     Abstract available


  162. WELCH MD, Howlett M, Halse HM, Greene WK, et al
    Novel CT domain-encoding splice forms of CTGF/CCN2 are expressed in B-lineage acute lymphoblastic leukaemia.
    Leuk Res. 2015;39:913-20.
    PubMed     Text format     Abstract available


  163. NUMATA M, Yener MD, Ekmekci SS, Aydin M, et al
    High MN1 expression increases the in vitro clonogenic activity of primary mouse B-cells.
    Leuk Res. 2015;39:906-12.
    PubMed     Text format     Abstract available


  164. RAMOS TL, Sanchez-Abarca LI, Lopez-Ruano G, Muntion S, et al
    Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
    Leuk Res. 2015;39:921-4.
    PubMed     Text format     Abstract available


  165. ANDRIANI A, Montanaro M, Voso MT, Villiva N, et al
    Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.
    Leuk Res. 2015;39:801-4.
    PubMed     Text format     Abstract available


  166. TAKEUCHI A, Nishioka C, Ikezoe T, Yang J, et al
    STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
    Leuk Res. 2015;39:897-905.
    PubMed     Text format     Abstract available


  167. ADAMAKI M, Lambrou GI, Athanasiadou A, Vlahopoulos S, et al
    HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival.
    Leuk Res. 2015;39:874-82.
    PubMed     Text format     Abstract available


  168. MASAROVA L, Newberry KJ, Pierce SA, Estrov Z, et al
    Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.
    Leuk Res. 2015;39:822-7.
    PubMed     Text format     Abstract available


  169. LEBON D, Vergez F, Bertoli S, Harrivel V, et al
    Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.
    Leuk Res. 2015;39:818-21.
    PubMed     Text format     Abstract available


    July 2015
  170. LAURENTI L, Innocenti I, Autore F, Vannata B, et al
    Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
    Leuk Res. 2015 Jul 26. pii: S0145-2126(15)30352.
    PubMed     Text format     Abstract available


  171. VIANA SS, de Lima LM, do Nascimento JB, Cardoso CA, et al
    Secular trends and predictors of mortality in acute lymphoblastic leukemia for children of low socioeconomic level in Northeast Brazil.
    Leuk Res. 2015 Jul 26. pii: S0145-2126(15)30350.
    PubMed     Text format     Abstract available


  172. CALVO X, Nomdedeu M, Santacruz R, Martinez N, et al
    Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of pro
    Leuk Res. 2015 Jul 23. pii: S0145-2126(15)30324.
    PubMed     Text format     Abstract available


  173. BRECCIA M, Efficace F, Sica S, Abruzzese E, et al
    Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
    Leuk Res. 2015 Jul 14. pii: S0145-2126(15)30347.
    PubMed     Text format     Abstract available


  174. SZWED M, Kania KD, Jozwiak Z
    Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/beta-catenin pathway in human leukemia cells.
    Leuk Res. 2015 Jul 13. pii: S0145-2126(15)30346.
    PubMed     Text format     Abstract available


  175. ZHANG YY, Yao DM, Zhu XW, Zhou JD, et al
    DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia.
    Leuk Res. 2015 Jul 6. pii: S0145-2126(15)30341.
    PubMed     Text format     Abstract available


  176. AZIMI F, Mortazavi Y, Alavi S, Khalili M, et al
    Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
    Leuk Res. 2015 Jul 4. pii: S0145-2126(15)30343.
    PubMed     Text format     Abstract available


  177. LOU Y, Ma Y, Suo S, Ni W, et al
    Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Leuk Res. 2015 Jul 2. pii: S0145-2126(15)00188.
    PubMed     Text format     Abstract available


  178. DRUSBOSKY L, Gars E, Trujillo A, McGee C, et al
    Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
    Leuk Res. 2015 Jul 2. pii: S0145-2126(15)00187.
    PubMed     Text format     Abstract available


  179. MORAD SA, Davis TS, Kester M, Loughran TP Jr, et al
    Dynamics of ceramide generation and metabolism in response to fenretinide - Diversity within and among leukemia.
    Leuk Res. 2015 Jul 2. pii: S0145-2126(15)30335.
    PubMed     Text format     Abstract available


  180. GOSSE G, Celton M, Lamontagne V, Forest A, et al
    Whole genome and transcriptome analysis of a novel AML cell line with a normal karyotype.
    Leuk Res. 2015;39:709-18.
    PubMed     Text format     Abstract available


    June 2015
  181. HUCK A, Pozdnyakova O, Brunner A, Higgins JM, et al
    Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia.
    Leuk Res. 2015 Jun 28. pii: S0145-2126(15)30336.
    PubMed     Text format     Abstract available


  182. FOZZA C, Corda G, Barraqueddu F, Virdis P, et al
    Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Leuk Res. 2015 Jun 26. pii: S0145-2126(15)30333.
    PubMed     Text format     Abstract available


  183. MIYATA S, Fukuda Y, Tojima H, Matsuzaki K, et al
    Mechanism of the inhibition of leukemia cell growth and induction of apoptosis through the activation of ATR and PTEN by the topoisomerase inhibitor 3EZ, 20Ac-ingenol.
    Leuk Res. 2015 Jun 14. pii: S0145-2126(15)30331.
    PubMed     Text format     Abstract available


  184. CHEN C, Bartenhagen C, Gombert M, Okpanyi V, et al
    Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Leuk Res. 2015 Jun 14. pii: S0145-2126(15)30332.
    PubMed     Text format     Abstract available


  185. BADAR T, Kantarjian HM, Ravandi F, Jabbour E, et al
    Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
    Leuk Res. 2015 Jun 11. pii: S0145-2126(15)30330.
    PubMed     Text format     Abstract available


  186. CHEN S, Xing H, Li S, Yu J, et al
    Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
    Leuk Res. 2015 Jun 10. pii: S0145-2126(15)30329.
    PubMed     Text format     Abstract available


  187. AHMED T, Holwerda S, Klepin HD, Isom S, et al
    High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
    Leuk Res. 2015 Jun 1. pii: S0145-2126(15)30326.
    PubMed     Text format     Abstract available


  188. SHI R, Munker R
    Survival of patients with mixed phenotype acute leukemias: A large population-based study.
    Leuk Res. 2015;39:606-16.
    PubMed     Text format     Abstract available


    May 2015
  189. SALEMI D, Cammarata G, Agueli C, Augugliaro L, et al
    miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
    Leuk Res. 2015 May 28. pii: S0145-2126(15)00128.
    PubMed     Text format     Abstract available


  190. MORABITO F, Cutrona G, Mosca L, D'Anca M, et al
    Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
    Leuk Res. 2015 May 19. pii: S0145-2126(15)00149.
    PubMed     Text format     Abstract available


  191. BASTIDA JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, et al
    Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome.
    Leuk Res. 2015 May 14. pii: S0145-2126(15)00133.
    PubMed     Text format     Abstract available


  192. DROLLE H, Wagner M, Vasold J, Kutt A, et al
    Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy.
    Leuk Res. 2015 May 7. pii: S0145-2126(15)00130.
    PubMed     Text format     Abstract available


  193. CRESCENZI B, Nofrini V, Barba G, Matteucci C, et al
    NUP98/11p15 translocations affect CD34+ cells in myeloid and T lymphoid leukemias.
    Leuk Res. 2015 May 7. pii: S0145-2126(15)00125.
    PubMed     Text format     Abstract available


  194. YUAN X, Koehn J, Hogge DE
    Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function.
    Leuk Res. 2015 May 4. pii: S0145-2126(15)00129.
    PubMed     Text format     Abstract available


  195. LAFARGE ST, Hou S, Pauls SD, Johnston JB, et al
    Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70.
    Leuk Res. 2015 May 2. pii: S0145-2126(15)00127.
    PubMed     Text format     Abstract available


  196. REAGAN JL, Sullivan MR, Winer ES, Lansigan F, et al
    Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
    Leuk Res. 2015 May 2. pii: S0145-2126(15)00126.
    PubMed     Text format     Abstract available


    April 2015
  197. EMADI A, Sadowska M, Carter-Cooper B, Bhatnagar V, et al
    Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.
    Leuk Res. 2015 Apr 30. pii: S0145-2126(15)00104.
    PubMed     Text format     Abstract available


  198. MINETTO P, Guolo F, Clavio M, De Astis E, et al
    Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
    Leuk Res. 2015 Apr 27. pii: S0145-2126(15)00122.
    PubMed     Text format     Abstract available


  199. KHARFAN-DABAJA MA, Labopin M, Bazarbachi A, Socie G, et al
    Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Leuk Res. 2015 Apr 24. pii: S0145-2126(15)00120.
    PubMed     Text format     Abstract available


  200. LIU L, Qu Q, Jiao W, Zhang Y, et al
    Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Leuk Res. 2015 Apr 20. pii: S0145-2126(15)00117.
    PubMed     Text format     Abstract available


  201. KONUMA T, Kato S, Ishii H, Oiwa-Monna M, et al
    Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
    Leuk Res. 2015 Apr 7. pii: S0145-2126(15)00093.
    PubMed     Text format     Abstract available


  202. MUNCH C, Dragoi D, Frey AV, Thurig K, et al
    Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Leuk Res. 2015;39:462-70.
    PubMed     Text format     Abstract available


  203. SMITH AM, Little EB, Zivanovic A, Hong P, et al
    Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
    Leuk Res. 2015;39:435-44.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: